NCT03936049View on ClinicalTrials.gov

Replication of the LEADER Diabetes Trial in Healthcare Claims

CompletedOBSERVATIONAL
Enrollment

168,690

Participants

Timeline

Start Date

September 22, 2017

Primary Completion Date

February 18, 2021

Study Completion Date

February 18, 2021

Conditions
Diabetes
Interventions
DRUG

Liraglutide

Liraglutide dispensing claim is used as the exposure group

DRUG

DPP-4 inhibitor

DPP-4 inhibitor dispensing claim is used as the reference group

Trial Locations (1)

02120

Brigham And Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT03936049 - Replication of the LEADER Diabetes Trial in Healthcare Claims | Biotech Hunter | Biotech Hunter